Highlight
The BRIGHT trial is a pivotal randomized controlled study assessing AspyreRx, an FDA-approved digital therapeutic that delivers cognitive behavioral therapy to improve glycemic control in patients with type 2 diabetes who experience residual hyperglycemia despite stable pharmacotherapy. The trial adopts a pragmatic, virtual, and decentralized design to enhance the generalizability of findings across diverse clinical settings. It aims to establish both short-term (90 and 180 days) and long-term efficacy and safety outcomes, alongside impacts on healthcare utilization and medication use.
